In the realm of personalized medicine, the role of genetic testing in cancer treatment has become increasingly significant. Among the forefront of these advancements are the Oncomine Comprehensive Panel and the Oncomine Tumor Mutation Burden (TMB), Microsatellite Instability (MSI), and Programmed Death-Ligand 1 (PD-L1) tests. These tests are pivotal in identifying genetic mutations and alterations […]
